Share This:
https://ntp.niehs.nih.gov/go/18981

Target Organs and Levels of Evidence for GMM-10

Toxicology Study of Diispropylcarbodiimide (CASRN 693-13-0) in Genetically Modified (FVB Tg.AC Hemizygous) Mice and Carcinogenicity Study of Diispropylcarbodiimide in Genetically Modified [B6.129-Trp53tm1Brd (N5) Haploinsufficient] Mice (Dermal Studies)

Chemical (Study Title)
CASRN
Peer Review Date Primary Uses Route/Exposure Levels Study Laboratory
Diisopropylcarbodiimide
693-13-0
09/28/2005 As a peptide coupling reagent; as a condensing reagent in dipeptide synthesis; in preparation of polyimide precursor coatings for electrophoretic image display fabrication; as a military nerve agent stabilizer. Topical Application
Female Mice: 0, 4.38, 8.75, 17.5, 35, or 70 mg/kg; 10/group
BioReliance, Inc
Levels of evidence information forToxicology Study of Diisopropylcarbodiimide in Female Tg.AC Hemizygous Mice
  Female Tg.AC Hemizygous Mice
  20 Weeks
Neoplastic Lesions None
Non-Neoplastic Lesions None




Levels of evidence information forCarcinogenesis Study of Diisopropylcarbodiimide in Female p53 Haploinsufficient Mice
  Female p53 Haploinsufficient Mice
  27 Weeks
Levels of Evidence No Evidence
Neoplastic Lesions None
Non-Neoplastic Lesions
  • Skin: epidermal hyperplasia